Schizophrenia is a mental disorder characterized by both positive and negative symptoms that impair the mental function of the affected individual. Positive symptoms typically include paranoia, hallucinations and delusions, and are usually treatable. Negative symptoms include asociality (lack of, or reduced, social interaction) and cognitive impairment and are largely untreatable with current drug therapy. As such, there is a clear unmet clinical need for medications that are active and effective against the negative symptoms of schizophrenia.
Charles River has validated a pencyclidine (PCP)-induced deficit model which recapitulates several behavioral deficits, mimicking the symptoms of schizophrenia. This model displays both positive and negative symptoms, including cognitive deficits, and facilitates the development of drugs for either symptom category or in combination.